Alligator Bioscience AB (publ)
SSE:ATORX.ST
1.178 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 58.107 | 35.696 | 12.943 | 4.352 | 4.358 | 26.959 | 56.875 | 58.24 | 289.797 | 1.234 |
Cost of Revenue
| 218.792 | 147.725 | 86.982 | 82.32 | 145.375 | 121.162 | 3.204 | 2.553 | 31.043 | 44.842 |
Gross Profit
| -160.685 | -112.029 | -74.039 | -77.968 | -141.017 | -94.203 | 53.671 | 55.687 | 258.754 | -43.608 |
Gross Profit Ratio
| -2.765 | -3.138 | -5.72 | -17.915 | -32.358 | -3.494 | 0.944 | 0.956 | 0.893 | -35.339 |
Reseach & Development Expenses
| 264.585 | 134.926 | 68.038 | 69.102 | 132.016 | 102.921 | 60.335 | 39.805 | 49.49 | 42.352 |
General & Administrative Expenses
| 0 | 0 | 18.944 | 13.218 | 13.359 | 18.241 | 18.61 | 23.473 | 49.335 | 48.605 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 35.81 | 31.213 | 18.944 | 13.218 | 13.359 | 18.241 | 18.61 | 23.473 | 49.335 | 48.605 |
Other Expenses
| 104.091 | 93.072 | 67.323 | 66.068 | 72.154 | 57.978 | 40.958 | 29.548 | 39.452 | 28.545 |
Operating Expenses
| 300.395 | 227.998 | 154.305 | 148.388 | 217.529 | 179.14 | 119.903 | 92.826 | 88.787 | 77.15 |
Operating Income
| -252.777 | -192.789 | -141.565 | -144.298 | -214.519 | -153.08 | -62.299 | -56.081 | 203.006 | -77.213 |
Operating Income Ratio
| -4.35 | -5.401 | -10.938 | -33.157 | -49.224 | -5.678 | -1.095 | -0.963 | 0.701 | -62.571 |
Total Other Income Expenses Net
| 4.191 | -0.614 | -0.171 | 1.002 | 4.407 | 2.138 | -0.73 | -13.77 | 6.367 | 0.368 |
Income Before Tax
| -248.586 | -193.403 | -141.736 | -143.296 | -210.112 | -150.043 | -63.758 | -48.356 | 207.377 | -76.782 |
Income Before Tax Ratio
| -4.278 | -5.418 | -10.951 | -32.926 | -48.213 | -5.566 | -1.121 | -0.83 | 0.716 | -62.222 |
Income Tax Expense
| 10.321 | -0.006 | 0.231 | 0.313 | 0.419 | 2.138 | -0.711 | 8.354 | 6.368 | 0.369 |
Net Income
| -248.586 | -193.397 | -141.967 | -143.609 | -210.531 | -150.043 | -63.758 | -48.356 | 207.377 | -76.782 |
Net Income Ratio
| -4.278 | -5.418 | -10.969 | -32.998 | -48.309 | -5.566 | -1.121 | -0.83 | 0.716 | -62.222 |
EPS
| -0.55 | -0.88 | -0.96 | -1.22 | -1.57 | -1.12 | -0.48 | -0.43 | 1.87 | -0.58 |
EPS Diluted
| -0.55 | -0.88 | -0.96 | -1.22 | -1.57 | -1.12 | -0.48 | -0.43 | 1.58 | -0.58 |
EBITDA
| -242.288 | -180.996 | -130.361 | -131.461 | -198.145 | -144.131 | -60.535 | -1.557 | 220.045 | -73.595 |
EBITDA Ratio
| -4.17 | -5.07 | -10.072 | -30.207 | -45.467 | -5.346 | -1.064 | -0.027 | 0.759 | -59.639 |